 |
市場調査レポート
代謝関連の各種提携契約：契約条件・合意内容Global Metabolic Partnering 2010-2017: Deal trends, players and financials |
||||||
| 発行 | Current Partnering, a division of Wildwood Ventures Limited | 商品コード | 250301 | ||||
| 出版日 | ページ情報 | 英文 納期: 即日から翌営業日 |
|||||
| 価格 |
|
||||||
| 代謝関連の各種提携契約：契約条件・合意内容 Global Metabolic Partnering 2010-2017: Deal trends, players and financials | ||
| 出版日: 2017年09月01日 | ページ情報: 英文 |
|
当レポートでは、2007年以降の代謝関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約区分・開発ステージ・技術区分・適応症区分別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。
※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。
Global Metabolic Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.
‘Global Metabolic Partnering 2010 to 2017’ provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Metabolic dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Metabolic deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Metabolic deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2010. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.
‘Global Metabolic Partnering 2010 to 2017’ is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.
‘Global Metabolic Partnering 2010 to 2017’ includes:
The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.
In ‘Global Metabolic Partnering 2010 to 2017’, available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The ‘Global Metabolic Partnering 2010-2017’ report provides comprehensive access to available deals and contract documents for over 1,000 metabolic deals. Analyzing actual contract agreements allows assessment of the following:
‘Global Metabolic Partnering 2010 to 2017’ provides the reader with the following key benefits:
